Special Issue "Novel Translational Approaches to the Treatment of Coronary Artery Disease and Congenital Heart Disease in Comorbid Patients"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: 15 October 2020.

Special Issue Editor

Dr. Anton G. Kutikhin
Guest Editor
Head of the Laboratory for Vascular Biology, Division of Experimental Medicine, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia
Interests: vascular biology; atherosclerosis; endothelial dysfunction; intimal hyperplasia; vascular inflammation; vasa vasorum; calcification; calciprotein particles

Special Issue Information

Dear Colleagues,

Current advances in the treatment of cardiovascular disease have become possible primarily owing to the synergy among vascular biology, vascular tissue engineering, and translational and clinical medicine. Discoveries made on the bench are now efficiently translated into preclinical testing on conventional and genetically modified animal models, and the most significant breakthroughs enter the clinical trials. However, aging of the population, characterized by a large proportion of patients having co-occurring diseases (multiple morbidities), represents a major challenge for cardiovascular medicine and requires significant efforts to improve the outcome.

Rapid development of visualization techniques, including molecular imaging, has provided unique insights into cardiovascular pathology and identified a number of promising therapeutic targets. Further, it has allowed the implementation of novel surgical modalities employing vascular tissue engineering products, for instance, biodegradable vascular grafts, drug-eluting stents, and bioprosthetic heart valves. The advent and dissemination of high-throughput approaches to analyze the genome, transcriptome, proteome, and metabolome have resulted in significant discoveries in vascular biology which has conceptualized our understanding of the cardiovascular system and suggested the potential culprits of cardiovascular disease. Active interactions between basic scientists, clinicians, industry, and policy makers have cumulatively led to a lot of perspective projects, the results of which have only recently been obtained or are being expected in the nearest future.

The present Special Issue aims to summarize the newest advances in cardiovascular translational research with respect to comorbid patients which represent a clinical setting increasingly becoming more and more important. It highlights the most promising therapeutic targets found in pathophysiology studies and novel efficient surgical interventions. Importantly, it also sheds light on recent advances in vascular tissue engineering, in particular, preclinical development of small-diameter vascular prostheses and transcatheter heart valves. The issue contains both exemplary original research studies and comprehensive review articles critically discussing the existing knowledge in the field.

Dr. Anton G. Kutikhin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Heart
  • Blood vessels
  • Cardiovascular disease
  • Coronary artery disease
  • Ischemic heart disease
  • Coronary heart disease
  • Acute coronary syndrome
  • Angina pectoris
  • Stable angina
  • Unstable angina
  • Myocardial infarction
  • Cardiac arrhythmia
  • Atrial fibrillation
  • Ventricular fibrillation
  • Heart block
  • Heart failure
  • Congenital heart disease
  • Tetralogy of fallot
  • Comorbidity
  • Multimorbidity
  • Multiple morbidities
  • Comorbid patients
  • Overweight
  • Obesity
  • Diabetes mellitus
  • Chronic obstructive pulmonary disease
  • Chronic kidney disease
  • Cognitive impairment
  • Myocardial revascularization
  • Percutaneous coronary intervention
  • Coronary artery bypass graft surgery
  • Preclinical development
  • Animal testing
  • Clinical trials
  • Vascular tissue engineering
  • Cognitive therapy
  • Cardiac remodeling
  • Cardiac fibrosis
  • Cardiac regeneration
  • Endothelial dysfunction
  • Atherosclerosis
  • In-stent restenosis
  • Thrombosis
  • Intimal hyperplasia
  • Vascular inflammation
  • Calcification
  • Plaque rupture
  • Cardiomyocytes
  • (myo)fibroblasts
  • Endothelium
  • Vascular smooth muscle cells
  • Macrophages
  • Epicardial adipose tissue
  • Perivascular adipose tissue
  • Subcutaneous adipose tissue
  • Platelets

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Open AccessCommunication
A Brief Report on an Implantation of Small-Caliber Biodegradable Vascular Grafts in a Carotid Artery of the Sheep
Pharmaceuticals 2020, 13(5), 101; https://doi.org/10.3390/ph13050101 - 21 May 2020
The development of novel biodegradable vascular grafts of a small diameter (<6 mm) is an unmet clinical need for patients requiring arterial replacement. Here we performed a pre-clinical study of new small-caliber biodegradable vascular grafts using a sheep model of carotid artery implantation. [...] Read more.
The development of novel biodegradable vascular grafts of a small diameter (<6 mm) is an unmet clinical need for patients requiring arterial replacement. Here we performed a pre-clinical study of new small-caliber biodegradable vascular grafts using a sheep model of carotid artery implantation. The 4 mm diameter vascular grafts were manufactured using a mix of polyhydroxybutyrate/valerate and polycaprolactone supplemented with growth factors VEGF, bFGF and SDF-1α (PHBV/PCL-GFmix) and additionally modified by a polymer hydrogel coating with incorporation of drugs heparin and iloprost (PHBV/PCL-GFmixHep/Ilo). Animals with carotid artery autograft implantation and those implanted with clinically used GORE-TEX® grafts were used as control groups. We observed that 24 h following surgery, animals with carotid artery autograft implantation showed 87.5% patency, while all the PHBV/PCL-GFmix and GORE-TEX® grafts displayed thrombosis. PHBV/PCL-GFmixHep/Ilo grafts demonstrated 62.5% patency 24 h following surgery and it had remained at 50% 1 year post-operation. All the PHBV/PCL grafts completely degraded less than 1 year following surgery and were replaced by de novo vasculature without evidence of calcification. On the other hand, GORE-TEX® grafts displayed substantial amounts of calcium deposits throughout graft tissues. Thus, here we report a potential clinical usefulness of PHBV/PCL grafts upon their additional modification by growth factors and drugs to promote endothelialization and reduce thrombogenicity. Full article
Back to TopTop